Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endoscopic Ultrasound Plus Submucosal Injection for Early Esophageal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Sun Yat-sen University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Jian-jun Li, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT01555801
First received: February 29, 2012
Last updated: March 14, 2012
Last verified: March 2012

February 29, 2012
March 14, 2012
February 2012
September 2012   (final data collection date for primary outcome measure)
  • Sensitivity [ Time Frame: Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days ] [ Designated as safety issue: No ]
    The stages judged from submucosal injection plus EUS or ordinary EUS will be compared with the pathological results after endoscopic or surgical resection.So the sensitivity,specificity,positive predictive value,negative predictive value and diagnostic accuracy of either submucosal injection plus EUS or ordinary EUS for early esophageal cancer will be measured respectivly.
  • Specificity [ Time Frame: Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days ] [ Designated as safety issue: No ]
    As well as sensitivity described above.
  • Diagnostic accuracy [ Time Frame: Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days ] [ Designated as safety issue: No ]
    As well as sensitivity described above.
Same as current
Complete list of historical versions of study NCT01555801 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Endoscopic Ultrasound Plus Submucosal Injection for Early Esophageal Cancer
Efficacy Study of Endoscopic Ultrasound Combining With Submucosal Saline Injection for Pretreatment Staging of T1a and T1b in Patients With Early Esophageal Cancer

Preoperative accurately staging T1a or T1b in early esophageal cancer is vital for the choices of treatment. At present, the main diagnostic method for early esophageal cancer is endoscopic ultrasound (EUS). However, the accuracy of EUS alone is poor. Thus, it is necessary to improve endoscopic ultrasound examination methods. This project is concerning on the efficacy of EUS combining with submucosal injection of saline for staging T1a and T1b-esophageal cancer. Patients and methods: 80 cases of pathological confirmed early esophageal cancer were randomly divided into two groups: endoscopic ultrasonography group (EUS group) and EUS combining with submucosal injecting saline group (EUS+SIS group). All the cases will be performance by endoscopic or surgical resection; postoperative pathologic diagnosis will be obtained involving echo, depth, margin and other features. The EUS results of two groups of patients will be compared with pathologic results. From comparison, the efficacy and accuracy of EUS+SIS for staging T1a and T1b in esophageal cancer patients will be validated. Through this study, the investigators may develop a routine diagnostic and accurately staging method for early esophageal cancer patients.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Diagnostic
Esophageal Cancer
  • Device: submucosal injection needle ; EUS
    The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
    Other Names:
    • submucosal injection needle:Olympus,NM-20K-0423;
    • EUS:Olympus,UM2000
  • Device: ordinary endosonography(EUS)
    These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
    Other Name: EUS:Olympus,UM2000
  • Experimental: Submucosal injection combining with EUS
    The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
    Intervention: Device: submucosal injection needle ; EUS
  • Placebo Comparator: ordinary endosonography(EUS)
    The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
    Intervention: Device: ordinary endosonography(EUS)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
September 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-65 years old, no gender limited;
  • Patients with esophageal squamous cell carcinoma who be confirmed by ordinary endoscopy and pathologic biopsy;
  • Patients who agree to accept endoscopic resection or surgical excision of the lesion in esophagus;
  • patients with normal cardio-pulmonary function and normal coagulative function,are predicted to be tolerated anesthesia and surgery;
  • patients who understand test purpose, volunteer to join these study and sign the consent inform.

Exclusion Criteria:

  • Patients with stages of T2, T3, or T4 displayed by EUS;
  • Patients who can't tolerate endoscopy and surgical treatment for various reasons;
  • Patients who have distant metastasis, or multiple source of malignant tumors;
  • Patients with blood coagulative disorder;
  • Patients don't accept the endoscopic examination or surgical treatment;
  • Patients with poor compliancy.
Both
18 Years to 65 Years
No
Contact: Jian-jun Li, M.D. Ph.D. 86-2087343381 lijj@sysucc.org.cn
China
 
NCT01555801
112273, 1122
Yes
Jian-jun Li, Sun Yat-sen University
Sun Yat-sen University
Not Provided
Principal Investigator: Jian-jun Li, M.D. Sun Yat-sen University
Sun Yat-sen University
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP